


**VERTEX PHARM. INC. NDAQ:VRTX** RECENT PRICE **339.97** P/E RATIO **26.2** (Trailing: 27.1; Median: NMF) RELATIVE P/E RATIO **1.58** DIV'D YLD **Nil** **VALUE LINE**

<b>TIMELINESS</b> 3 Lowered 3/31/23	High: 66.1	90.0	124.4	143.5	125.0	167.9	194.9	225.7	306.1	243.0	324.8	354.5	Target Price Range		
<b>SAFETY</b> 2 Raised 9/3/21	Low: 32.0	42.7	59.8	97.4	71.5	73.3	144.1	161.0	197.5	176.4	214.7	282.2	2026	2027	2028
<b>TECHNICAL</b> 2 Raised 6/2/23	<b>LEGENDS</b>														
<b>BETA</b> .75 (1.00 = Market)	..... Relative Price Strength														
Options: Yes															
Shaded area indicates recession															

**18-Month Target Price Range**

Low-High Midpoint (% to Mid)

\$231-\$415 \$323 (-5%)



2026-28 PROJECTIONS		© VALUE LINE PUB. LLC											26-28			
High	Price	Gain	Ann'l Total													
Low	(+50%)	(+10%)	Return													
505			10%													
370			2%													

Institutional Decisions		Percent	
2022	3022	4022	shares
to Buy	480	532	75
to Sell	509	470	50
Hds(000)	234728	435256	25

2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	REVENUES per sh	
1.50	1.16	.51	.70	6.74	7.03	5.18	2.40	4.19	6.86	9.83	11.94	16.07	23.88	29.76	34.75	<b>38.05</b>	<b>40.80</b>	50.00	
d2.74	d2.83	d3.06	d3.56	.31	d.32	d1.70	d2.79	d2.01	1.28	2.38	4.96	10.86	9.70	13.50	<b>13.85</b>	<b>15.30</b>	18.75		
d3.03	d3.27	d3.71	d3.77	.14	d.50	d1.98	d3.14	d2.31	d.46	1.04	2.06	4.51	10.29	9.01	12.82	<b>13.00</b>	<b>14.50</b>	17.50	
--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	<b>Nil</b>	<b>Nil</b>	Nil	
.24	.21	.12	.19	.17	.33	.22	.21	.18	.23	.39	.37	.29	1.00	.92	.80	<b>.90</b>	<b>1.00</b>	1.20	
2.04	1.58	5.48	2.48	3.76	4.60	5.80	4.45	3.82	4.66	8.01	17.38	23.50	33.43	39.69	54.13	<b>64.70</b>	<b>79.20</b>	120.00	
132.88	151.25	199.96	203.52	209.30	217.29	233.79	241.76	246.31	248.30	253.25	255.17	258.99	259.89	254.48	257.01	<b>255.00</b>	<b>255.00</b>	250.00	
--	--	--	--	NMF	--	--	--	--	--	NMF	NMF	41.2	24.6	22.8	21.4	<i>Bold figures are Value Line estimates</i>		25.0	
--	--	--	--	NMF	--	--	--	--	--	NMF	NMF	2.19	1.26	1.23	1.23			1.40	
--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--			Nil	

CAPITAL STRUCTURE as of 3/31/23		REVENUES (\$MILL)		OPERATING MARGIN		DEPRECIATION (\$MILL)	
Total Debt	None	1212.0	580.4	1032.3	1702.2	2488.7	3047.6
		NMF	NMF	NMF	4.3%	18.3%	24.2%
		48.4	63.3	62.3	61.4	61.4	72.4
		d445.0	d737.6	d556.3	d112.1	263.5	533.7
		--	--	--	--	--	--
		1190.8	1178.2	900.8	1039.0	1841.7	2722.8
		48.8	319.9	266.9	35.0	20.5	19.7
		1356.4	1075.0	940.0	1156.6	2028.6	4435.2
		NMF	NMF	NMF	NMF	12.9%	12.0%
		NMF	NMF	NMF	NMF	13.0%	12.0%
		NMF	NMF	NMF	NMF	13.0%	12.0%
		--	--	--	--	--	--

**Despite a mixed start to the year, we remain upbeat about Vertex Pharmaceuticals' growth prospects.** First-quarter revenue rose 13%, year over year, thanks largely to the continued strong sales uptake of *Trikafta* (*Kaftrio* in the EU), a triple-drug blend of elexacaftor, tezacaftor, and ivacaftor approved for treating cystic fibrosis (CF), a debilitating lung disease. But costs to advance mid- and late-stage clinical programs and launch new drugs, along with foreign currency headwinds, weighed on the bottom line. Even so, with label expansions on key CF therapies ongoing, and additional reimbursements obtained in markets outside the U.S., revenues in 2023 appear to be on track to rise to \$9.55 billion-\$9.7 billion. And though we've lowered our share-profit call by \$0.50 to reflect the first-quarter result, earnings should reach a record level this year, too, with more gains likely as late decade approaches.

**A biologic product may soon get the regulatory green light.** In collaboration with CRISPR Therapeutics, Vertex recently developed a gene-editing therapy called exa-cel (formerly CXTX001), targeting beta thalassemia and severe sickle cell disease. The company, which has filed biologics licensing applications, is hoping to get an accelerated review (eight months versus the standard 12) by the U.S. FDA; filings have been completed in the EU and U.K.

Cal-ender	QUARTERLY REVENUES (\$ Mill.)				Full Year
	Mar.31	Jun.30	Sep.30	Dec.31	
2020	1515.1	1524.5	1538.3	1627.8	6205.7
2021	1724.3	1793.4	1984.1	2072.6	7574.4
2022	2097.5	2196.2	2334.3	2302.7	8930.7
2023	2374.8	<b>2400</b>	<b>2450</b>	<b>2475.2</b>	<b>9700</b>
2024	<b>2550</b>	<b>2600</b>	<b>2600</b>	<b>2650</b>	<b>10400</b>

Cal-ender	EARNINGS PER SHARE A				Full Year
	Mar.31	Jun.30	Sep.30	Dec.31	
2020	2.29	3.18	2.53	2.30	10.29
2021	2.49	.26	3.28	3.00	9.01
2022	2.96	3.13	3.59	3.15	12.82
2023	2.69	<b>3.40</b>	<b>3.60</b>	<b>3.31</b>	<b>13.00</b>
2024	<b>3.50</b>	<b>3.70</b>	<b>3.80</b>	<b>3.50</b>	<b>14.50</b>

Cal-ender	QUARTERLY DIVIDENDS PAID				Full Year
	Mar.31	Jun.30	Sep.30	Dec.31	
2019					
2020	NO CASH DIVIDENDS				
2021	BEING PAID				
2022					
2023					

(A) Diluted earnings. Excl. non-recur. gain: '18, \$6.03 (one-time tax benefit). Qly. egs. may not sum due to difference in shs. outstg/rounding. Next egs. rpt. due early August.

(B) In millions. Note: share count in '13 reflects the conversion of convertible notes into 8.3 mill. shs.

(C) As of 12/31/22, had total net oper. loss carryforwards of about \$770.5 mill. and tax credits of \$295.0 million.

Company's Financial Strength A+  
 Stock's Price Stability 85  
 Price Growth Persistence 80  
 Earnings Predictability 30

**To subscribe call 1-800-VALUELINE**

© 2023 Value Line, Inc. All rights reserved. Factual material is obtained from sources believed to be reliable and is provided without warranties of any kind. THE PUBLISHER IS NOT RESPONSIBLE FOR ANY ERRORS OR OMISSIONS HEREIN. This publication is strictly for subscriber's own, non-commercial, internal use. No part of it may be reproduced, resold, stored or transmitted in any printed, electronic or other form, or used for generating or marketing any printed or electronic publication, service or product.